ZLLY.NEO ELI LILLY (LLY) BMO CDR (CAD HEDGED)

Healthcare Drug Manufacturers - General NEO Exchange
14.95 CAD
Close of Oct 30, 2026
Market cap
CAD 12.9B
P/E
0.4x
P/B
0.26x
ROE
69.3%
Dividend yield
0.55%
Fundamental score
3.2/5

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ZLLY.NEO undervalued?

Graham number

The Graham number of ELI LILLY (LLY) BMO CDR (CAD HEDGED) cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ELI LILLY (LLY) BMO CDR (CAD HEDGED) fundamental analysis

15 of 22 checks passed

ROE 2/2

High return on equity (69.3%), above 20%.

ROA 1/1

Return on assets (18.9%) is above the industry median (7.4%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (95.6%) is above the industry median (90.5%).

Revenue Growth 2/2

Revenue grew 31.7% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

High debt to equity (116.7%), above 100%.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 1/1

PE (0.4x) is below the market median (20.3x).

PE vs Industry 1/1

PE (0.4x) is below the industry median (25.0x).

PBV 1/1

Price to book (0.3x) is below the industry median (8.1x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 0.1, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 2/2

Dividend yield (74.0%) is in the top 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 26.1%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

ELI LILLY (LLY) BMO CDR (CAD HEDGED) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ELI LILLY (LLY) BMO CDR (CAD HEDGED)

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and…

Full company profile